A phase III study found that simeprevir-based regimens achieved high SVR12 rates in HCV genotype 4-infected patients. The study showed that response-guided therapy criteria were met by most treatment-naïve and prior-relapser patients, resulting in high SVR12 rates.
A study found that gut microbiota plays a role in the development of alcoholic liver disease, with fecal microbiota transplantation showing promise as a potential treatment. The research highlights the importance of restoring gut functionality and re-establishing intestinal flora.
The new interferon-free 3D regimen, consisting of ABT-450/R/ABT-267 and ABT-333 plus ribavirin, demonstrated consistently high cure rates across various patient types, including GT1a and compensated cirrhosis patients. The treatment achieved SVR12 rates of 96.2% in SAPPHIRE-I study participants.
Phase III study results show obeticholic acid produces meaningful biochemical improvements, including reduced ALP and bilirubin levels. The treatment also demonstrates significant clinical benefits, such as improved liver function parameters and a lower risk of liver transplantation and death.
Studies predict improved HCC patient outcomes with new diagnostic approaches. Gadoxetic acid-enhanced MRI shows higher detection sensitivity for early-stage HCC, potentially improving treatment outcomes by ensuring optimum care.
A UK study found a genetic variant associated with fatty liver disease severity in pediatric patients. Patients had low vitamin D blood levels throughout the year, and most samples were deficient or insufficient in vitamin D status compared to national health standards.
A new fixed-dose combination of sofosbuvir and ledipasvir shows high cure rates for HCV genotype 1 patients, with only mild side effects. The treatment achieves SVR12 rates of up to 99% without the use of ribavirin, which is associated with significant side effects.
A new single-tablet regimen of ledipasvir and sofosbuvir has proven highly effective in treating patients with HCV genotype 1, with cure rates ranging from 94% to 99%. The therapy shows promise for both first-time and previously treated patients, offering a simpler and more tolerable option than current treatments.
Studies show sequential combination therapy with peginterferon and nucleoside analogues results in high complete response and HBsAg loss rates. Baseline HBsAg level and rate of decline during treatment predict treatment response. Adding peginterferon to entecavir enhances response rates, viral decline, and facilitates discontinuation.
SBEL1, a compound isolated from Chinese herbal medicines, has been found to inhibit hepatitis C virus (HCV) activity by approximately 90%. It blocks virus entry and inhibits IRES-mediated translation, reducing HCV protein production and RNA replication.
A new oral combination therapy has been shown to cure hepatitis C infection in over 90% of patients with liver cirrhosis, providing a significant improvement over the current treatment options. The study found that the treatment was well-tolerated and resulted in no long-term relapses.